ADMA Biologics Inc (NASDAQ:ADMA) Shares Sold by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund decreased its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 17.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,223 shares of the biotechnology company's stock after selling 21,937 shares during the quarter. Illinois Municipal Retirement Fund's holdings in ADMA Biologics were worth $2,088,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of ADMA. Y Intercept Hong Kong Ltd acquired a new position in ADMA Biologics during the 4th quarter valued at approximately $510,000. Bank of New York Mellon Corp increased its stake in shares of ADMA Biologics by 10.8% in the fourth quarter. Bank of New York Mellon Corp now owns 1,521,166 shares of the biotechnology company's stock worth $26,088,000 after acquiring an additional 147,748 shares during the period. Oregon Public Employees Retirement Fund increased its stake in shares of ADMA Biologics by 1.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock worth $954,000 after acquiring an additional 700 shares during the period. Mutual of America Capital Management LLC increased its stake in shares of ADMA Biologics by 2.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock worth $614,000 after acquiring an additional 751 shares during the period. Finally, Jones Financial Companies Lllp increased its stake in shares of ADMA Biologics by 303.4% in the fourth quarter. Jones Financial Companies Lllp now owns 5,733 shares of the biotechnology company's stock worth $98,000 after acquiring an additional 4,312 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.

Insiders Place Their Bets

In other ADMA Biologics news, Director Jerrold B. Grossman sold 10,000 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the transaction, the director owned 478,194 shares of the company's stock, valued at $10,190,314.14. This represents a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Steve Elms sold 194,749 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the transaction, the director directly owned 87,330 shares in the company, valued at $1,767,559.20. The trade was a 69.04% decrease in their position. The disclosure for this sale can be found here. Insiders sold 464,621 shares of company stock valued at $9,644,269 in the last three months. 3.50% of the stock is currently owned by insiders.

ADMA Biologics Price Performance

NASDAQ ADMA traded up $0.26 during mid-day trading on Wednesday, hitting $18.14. The stock had a trading volume of 3,086,570 shares, compared to its average volume of 3,704,011. The firm's 50 day moving average is $20.40 and its 200 day moving average is $18.73. ADMA Biologics Inc has a twelve month low of $10.21 and a twelve month high of $25.67. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36. The stock has a market capitalization of $4.33 billion, a price-to-earnings ratio of 21.34 and a beta of 0.43.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The company had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. During the same period last year, the business earned $0.08 earnings per share. The firm's revenue was up 40.2% compared to the same quarter last year. Equities research analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ADMA shares. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th. Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Finally, Raymond James Financial increased their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.